The DOI matches its Crossref record; 13 of the 14 references it cites were found in a registry or an index.
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ApoE is strongly associated with the amount of fibrillar amyloid that deposits into plaques (28).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [28]
In the citing paper
“In addition to isoform status, it appears that the amount of apoE also plays a role in determining the extent of Aβ accumulation in the brain.”
From Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) · cites this paper as Bales et al., 1997
In the citing paper
“Initial studies clearly indicated that the deletion of the endogenous murine Apoe gene causes a dramatic decrease in fibrillar and total Aβ deposition in APP transgenic mouse models (Bales et al., 1997).”
From Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) · cites this paper as Bales et al., 1997
In the citing paper
“Previous studies demonstrated that the lack of apoE led to a dramatic decrease of amyloid deposition in APP transgenic mouse models (Bales et al., 1997; Holtzman et al., 2000b).”
From Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance (2009) · cites this paper as Bales et al., 1997
In the citing paper
“Previous studies demonstrated that the absence of apoE leads to a dramatic decrease in the levels of fibrillar Aβ deposits in APP transgenic mouse models (Bales et al., 1999; Bales et al., 1997; Holtzman et al., 2000a; Holtzman et al., 2000b).”
From Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance (2009) · cites this paper as Bales et al., 1997
In the citing paper
“Later, in vivo studies demonstrated that the lack of apoE led to a dramatic reduction of fibrillar Aβ deposition in APP transgenic mouse models (Bales et al., 1999; Bales et al., 1997; Holtzman et al., 2000a; Holtzman et al., 2000b).”
From Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance (2009) · cites this paper as Bales et al., 1997
In the citing paper
“Reducing ApoE in mouse models of amyloidosis greatly reduces plaque formation (7, 8, 33, 34).”
From The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Aβ amyloidosis (2015) · cites this paper as [33]
In the citing paper
“Both genetic deletion and pharmacological reduction of APOE reduced Aβ deposition in mouse models of AD. 3 , 4 , 5 , 6 , 7 , 8 , 9”
From Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors (2025) · cites this paper as [3]
In the citing paper
“Notably, deletion of Apoe reduces amyloid deposition in transgenic mouse models of AD. 3 , 4”
From Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors (2025) · cites this paper as [3]
In the citing paper
“Our findings remain consistent with the effects of apoE knock-out noted in several AD Tg mouse models, where lack of apoE was associated with absence of fibrillar Aβ deposits and prevented neurodegeneration [13,29,31,32].”
From Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice (2014) · cites this paper as [31]
In the citing paper
“Independent of apoE isoform, the amount of apoE in the brain appears to be critical for determining the extent of amyloid deposition [25,26].”
From Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling (2012) · cites this paper as [25]
In the citing paper
“ApoE gene deletion in APP transgenic mice leads to dramatically decreased amyloid plaques without affecting Aβ production (Bales et al., 1997).”
From Apolipoprotein E in Synaptic Plasticity and Alzheimer’s Disease: Potential Cellular and Molecular Mechanisms (2014) · cites this paper as Bales et al., 1997
In the citing paper
“The pivotal role of ApoE in brain Ab accumulation was confirmed by showing a marked reduction in Ab plaque and CAA deposits associated with the Apoe gene knockout (KO) in AD transgenic (Tg) mice.14”
From Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration (2013) · cites this paper as [14]
In the citing paper
“Similar effects of the ApoE KO were previously reported in APP V717F and APP SW lines, representing more latent models of Ab pathology in which thioflavin-S detects the first plaques around the age of 1 year.14,55”
From Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration (2013) · cites this paper as [14]
In the citing paper
“Reducing ApoE levels is generally protective in AD models1,4–6.”
From Decreased lipidated ApoE‐receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes (2025) · cites this paper as [4]
In the citing paper
“Previous studies showed that apoE is co-deposited in senile plaques and plays a crucial role in fibrillar plaque formation (23, 24).”
From APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia (2021) · cites this paper as [23]
In the citing paper
“In amyloid precursor proteineexpressing transgenic mice, deletion of mouse apoE gene inhibits development of fibrillar amyloid plaques [80,81].”
From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [80]
In the citing paper
“ApoE strongly regulates brain amyloid-β (Aβ) deposition in a dose- and isoform-dependent manner (E4>E3>E2) (Bales et al., 1997; Holtzman et al., 2000; Schmechel et al., 1993).”
From Overexpressing low‐density lipoprotein receptor reduces tau‐associated neurodegeneration in relation to apoE‐linked mechanisms (2021) · cites this paper as Bales et al., 1997
In the citing paper
“APP transgenic mice lacking endogenous mouse apoE display a significant decrease of amyloid pathology”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Bales et al 1997
In the citing paper
“apoE-deficient APP transgenic mice display virtually no fibrillar Aβ deposits nor neuritic degeneration”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Bales et al 1997
In the citing paper
“Initial studies using the PDAPP and Tg2576 APP transgenic mouse models that develop Aβ deposition demonstrated that the lack of murine apoE resulted in a significant decrease in Aβ deposition, along with an almost complete lack of true amyloid plaques and neuritic dystrophy (Bales et al., 1997; Holtzman et al., 2000; Holtzman et al., 1999).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Bales et al., 1997
In the citing paper
“Data from transgenic mouse models produced more conflicting results with impaired plaque deposition seen in mice lacking murine APOE (Bales et al., 1997; Holtzman et al., 2000), but also in animals overexpressing the human APOE3 or APOE4 isoforms (Holtzman et al., 1999).”
From The Pro-Neurotrophin Receptor Sortilin Is a Major Neuronal Apolipoprotein E Receptor for Catabolism of Amyloid-β Peptide in the Brain (2013) · cites this paper as Bales et al., 1997
In the citing paper
“Murine Apoe deletion reduced Aβ deposition in various transgenic APP mouse models (Bales, Verina et al. 1997, Bales, Verina et al. 1999, Holtzman, Fagan et al. 2000, Irizarry, Cheung et al. 2000, Ulrich, Ulland et al. 2018)”
From SORLA up-regulation suppresses pathological effects in aged tauopathy mouse brain (2026) · cites this paper as Bales, Verina et al. 1997
In the citing paper
“ApoE has a major impact on the generation of amyloid deposits in the AD mouse brain and deletion of ApoE in most AD mouse models significantly inhibits amyloid plaque formation [6], [7], [8].”
From Lack of LDL receptor enhances amyloid deposition and decreases glial response in an Alzheimer's disease mouse model (2011) · cites this paper as [8]
In the citing paper
“APP transgenic mice deficient for ApoE show a dramatic decrease in fibrillary amyloid deposits [5], [6], [7], [8], [9].”
From Lack of LDL receptor enhances amyloid deposition and decreases glial response in an Alzheimer's disease mouse model (2011) · cites this paper as [8]
In the citing paper
“Total body apoE knockout as well as astrocyte specific ApoE knockout results in markedly decreased fibrillar amyloid deposition and in less compact Aβ plaques as well as decreasing neuronal loss and reactive gliosis in a tauopathy model [96, 99, 100].”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [100]
In the citing paper
“In addition, the strongest genetic risk factor for LOAD, apolipoprotein E, APOE, in large part appears to increase risk via influencing Aβ seeding and clearance”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Bales et al., 1997
In the citing paper
“To date, substantial evidence has demonstrated ApoE affects amyloid-β deposition in a dosage and isoform-specific fashion (ApoE4>ApoE3>ApoE2)96–100”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [96]
In the citing paper
“Transgenic mouse studies confirmed that ApoE was necessary for the formation of fibrillar amyloid plaques and CAA [4, 5, 41, 61], however they also identified important differences between mouse and human ApoE.”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [5]
Citations
Cites
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Self-citationSpontaneous Hypercholesterolemia and Arterial Lesions in Mice Lacking Apolipoprotein E
Zhang, S. H., Reddick, R. L., Piedrahita, J. A., & Maeda, N. (1992) · Science · doi:10.1126/science.1411543 · Cited by 2,237
Apolipoprotein E polymorphism and Alzheimer's disease
Poirier, J., Bertrand, P., Poirier, J., Kogan, S., Gauthier, S., Poirier, J., Gauthier, S., Davignon, J., Bouthillier, D., & Davignon, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)91705-q · Cited by 1,108
Ma, J., Yee, A., Brewer, H. B., Das, S., & Potter, H. (1994) · Nature · doi:10.1038/372092a0 · Cited by 871
Normal and Abnormal Biology of the Beta-Amyloid Precursor Protein
Selkoe, D. J. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.002421 · Cited by 834
Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701
Apolipoprotein E and Alzheimer disease.
Strittmatter, W. J., & Roses, A. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4725 · Cited by 701
(1997) · doi:10.1073/pnas.94.4.1550 · Cited by 535
Human apolipoprotein E: the Alzheimer's disease connection
Weisgraber, K. H., & Mahley, R. W. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.13.8940294 · Cited by 333
Hyman, B. T., West, H. L., Rebeck, G. W., Buldyrev, S. V., Mantegna, R. N., Ukleja, M., Havlin, S., & Stanley, H. E. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3586 · Cited by 212
Research works printed but not linked: 2
- Kim, K.S. et al. Neurosci. Res. Comm. 51, 113–122 (1990).
- Brown, B.M. & Hettmansperger, T.P. J. Am. Stat. Assoc. 91, 1668–1675 (1996).
Cited by
Sorted by citations
Items 701–800 of 829
Dabbs, R. A., Wyatt, A. R., Yerbury, J. J., Ecroyd, H. W., & Wilson, M. R. (2010) · Topics in current chemistry · doi:10.1007/128_2010_85 · Cited by 2
Apolipoproteína E e Doença de Alzheimer
Prado, D., & Cardoso, I. L. (2013) · Revista Neurociências · doi:10.34024/rnc.2013.v21.8211 · Cited by 2
Genetics of Alzheimer’s Disease and Related Disorders
Hardy, J. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-661-4_1 · Cited by 2
Perspectives of Alzheimer's disease treatments
Davis, J. B., Bountra, C., & Richardson, J. C. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)01226-2 · Cited by 2
Holtzman, D. M. (2003) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200304002-00011 · Cited by 2
Linking cerebral malaria pathogenesis to APOE-mediated amyloidosisPreprint
Mwikali, K., Mwangi, S., Njunge, J. M., Berkley, J. A., Bejon, P., & Abdi, A. I. (2023) · Research Square · doi:10.21203/rs.3.rs-3512412/v1 · Cited by 2
Genetic Studies of Alzheimer's Disease
Blom, E. S. (2008) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 2
Contributions of the Glial Injury Response to the Multifactorial Pathogenesis of Alzheimer’s Disease
Mucke, L., Buttini, M., Mahley, R. W., Pitas, R. E., Raber, J., & Wyss‐Coray, T. (2000) · Research and perspectives in neurosciences · doi:10.1007/978-3-642-59643-8_3 · Cited by 2
Mahley, R. W. (2025) · Springer eBooks · doi:10.1007/978-3-031-52641-1_2-1 · Cited by 1
Protective mutations associated with APOE in Alzheimer’s disease
Ma, Y., Li, Y., Wu, G., Liu, L., Tian, M., Han, X., Chen, X., Xuan, X., Zheng, T., Gao, X., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03496-5 · Cited by 1
Cell-type-specific APOE4 cascade across the Alzheimer’s disease continuum
Shostak, D. M., Liang, Z., & Huang, Y. (2026) · Neuron · doi:10.1016/j.neuron.2026.04.024 · Cited by 1
Place cell physiology in a transgenic mouse model of Alzheimer's disease
Yi, M. (2009) · Cited by 1
APP-Based Transgenic Models: The PDAPP Model
Basak, J. M., & Holtzman, D. M. (2010) · Neuromethods · doi:10.1007/978-1-60761-898-0_18 · Cited by 1
Stephens, G. S., You, J. C., Fu, C.-H., & Chin, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.21126-7 · Cited by 1
Genetically Engineered Mouse Models of Neurodegenerative Disorders
Masliah, E., & Crews, L. A. (2007) · Springer eBooks · doi:10.1007/0-387-25919-8_19 · Cited by 1
Cruchaga, C., Kauwe, J. S. K., & Goate, A. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139025997.032 · Cited by 1
Alzheimer’s Disease and Frontotemporal Lobar Degeneration: Mouse Models
Ittner, L. M., Lee, W. S., Stefanoska, K., Asih, P. R., & Ke, Y. D. (2018) · Springer eBooks · doi:10.1007/978-3-319-72938-1_10 · Cited by 1
Lack of ApoE inhibits ADan amyloidosis in a mouse model of familial Danish dementia
Fernández, A., Gomez, M.-T., & Vidal, R. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102751 · Cited by 1
Genetic Factors in Alzheimer Disease and Dementia
Bird, T. D. (2009) · Springer eBooks · doi:10.1007/978-3-540-37654-5_28 · Cited by 1
Ostrovskа, S. S., Liholetov, E. О., Pavlova, V., Derkach, А. K., Shevchenko, I. F., & Adegova, L. Y. (2021) · Bulletin of Problems Biology and Medicine · doi:10.29254/2077-4214-2021-1-159-302-307 · Cited by 2
The Involvement of Aβ in the Neuroinflammatory Response
Eikelenboom, P., van Gool, W. A., Rozemüller, A. J. M., Scheper, W., Veerhuis, R., & Hoozemans, J. J. M. (2006) · Springer eBooks · doi:10.1007/978-1-84628-440-3_4 · Cited by 1
A systems perspective begins to emerge in Alzheimer's
Castellino, A. M. (1997) · Nature Biotechnology · doi:10.1038/nbt1297-1347 · Cited by 1
Luft, F. C. (2000) · Journal of Molecular Medicine · doi:10.1007/s001090000106 · Cited by 1
Apolipoprotein E: Structural and Functional Interactions with Amyloid β
Stine, W. B., & LaDu, M. J. (2005) · Wiley eBooks · doi:10.1002/9783527619344.ch10 · Cited by 1
Emerging strategies for the treatment of Alzheimer’s disease at the Millennium
Emmerling, M. R., Spiegel, K., Hall, E. D., LeVine, H., Walker, L. C., Schwarz, R. D., & Gracon, S. I. (1999) · Emerging Drugs · doi:10.1517/14728214.4.1.35 · Cited by 1
Pathogenesis and Mechanism of Cerebral Amyloidosis in APP Transgenic Mice
Jucker, M., Calhoun, M. E., Phinney, A. L., Stalder, M., Bondolfi, L., Winkler, D. T., Herzig, M. C., Pfeifer, M., Boncristiano, S., Tolnay, M., et al. (2001) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-662-04399-8_6 · Cited by 1
Genetically Engineered Models of Human Age-Related Neurodegenerative Diseases
Vickers, J. C. (2001) · Elsevier eBooks · doi:10.1016/b978-012351830-9/50027-5 · Cited by 1
APOE Impacts Lipid Trafficking in Retinal Pigment Epithelium CellsPreprint
Richards, S. E. V., Demirs, J. T., Jose, S., Fan, L., Xu, Y., Esterberg, R., Huang, C. L., Wilson, C. W., Saint‐Geniez, M., & Liao, S.-M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.30.596647 · Cited by 1
Murphy, K. B., Hu, D., Wolfs, L., Mancuso, R., Strooper, B. D., & Marzi, S. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.03.601874 · Cited by 1
SORLA upregulation suppresses global pathological effects in aged tauopathy mouse brainPreprint
Huang, H., Shi, C. H., Yang, W., Piña-Crespo, J., Bhatnagar, J., Curatolo, J., Murad, R., Shah, P. M., Campos, A. R., Houser, A. K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.25.661599 · Cited by 1
Inhibition of ApoE4 Endocytosis with LDLR-LA PeptidesPreprint
Park, S. H., Gomes, G.-N. W., Beyer, B. A., & Levine, Z. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.20.726622 · Cited by 1
Vascular Transport of Alzheimer’s Amyloid β Peptides and Apolipoproteins
Zloković, B. V., Ghiso, J. A., & Frangione, B. (2000) · Springer eBooks · doi:10.1007/978-94-017-1007-7_20 · Cited by 1
Schmechel, D. E., Xu, P., Gilbert, J. R., & Roses, A. D. (1999) · Springer eBooks · doi:10.1007/978-1-4615-4887-4_10 · Cited by 1
SORLA up-regulation suppresses pathological effects in aged tauopathy mouse brain
Huang, H., Shi, C. H., Yang, W., Piña-Crespo, J. C., Bhatnagar, J., Curatolo, J., Murad, R., Shah, P., Campos, A., Houser, A., et al. (2026) · Science Advances · doi:10.1126/sciadv.aed6825 · Cited by 1
Kordower (1999) · doi:10.1002/1531-8249(199909)46:3
Molecular Genetics and Molecular Biology of Alzheimer’s Disease
Sandbrink, R., & Beyreuther, K. T. (2001) · Springer eBooks · doi:10.1007/978-3-642-59519-6_72
Alzheimer’s Disease and Frontotemporal Lobar Degeneration: Mouse Models
van Eersel, J., Delerue, F., Ittner, L. M., & Ke, Y. D. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6380-0_8
Gandy, S. (2002) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-06274-6_15
The Role of Apolipoprotein E Concentration and Isoform in Amyloid-beta Metabolism In Vivo
Castellano, J. M. (2011) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7416v3s
Transgenic Mice Model in Alzheimer's Disease
Duan, X., & Y., G. (2002) · Hong Kong journal of psychiatry
Role of Oxidatively Stressed Lipids in Amyloid Formation and Toxicity
Axelsen, P. H., & Komatsu, H. (2010) · Wiley eBooks · doi:10.1002/9780470572702.ch27
Molecular genetics of Alzheimer's disease and other adult-onset dementias
George‐Hyslop, P. S. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511543555.030
Immunosignature of Alzheimer's Disease
Jimenez, L. R. (2011)
Modulating Amyloid Beta Clearance by Altering Cellular and Whole Brain Apolipoprotein E Metabolism
Basak, J. M. (2014) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7dz06bk
Implications of cholesterol and cholesterol-lowering therapy in Alzheimer s disease
Famer, D. (2007) · Figshare
Amyloid imaging in Alzheimer´s disease and mild cognitive impairment by Positron Emission Tomography
Forsberg, A. (2008) · Figshare
Genetic Basis of Resistance to Alzheimer’s Disease and Related Neurodegenerative Diseases
Masters, C. L., & Beyreuther, K. T. (2000) · Springer eBooks · doi:10.1007/978-3-642-56947-0_11
A Brief Introduction to the History of the β-Amyloid Protein (Aβ) of Alzheimer’s Disease
Small, D. H., & Barrow, C. J. (2006) · Springer eBooks · doi:10.1007/978-1-84628-440-3_1
Adlerz, L. (2007) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Tratamiento farmacológico del riesgo cardiovascular metabólico
Sánchez, J. M., & Gil-Guillén, V. F. (2003) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(03)71162-7
Characterization of the Alzheimer´s disease-associated clac protein
Söderberg, L. (2005) · Figshare
Costa, D. A. (2005) · Digital Commons - University of South Florida (University of South Florida)
Lipidated APOE has effects on cognitive function that are independent of amyloid-β pathology
Corona, A. W., & Landreth, G. E. (2015) · Brain · doi:10.1093/brain/awv300
Modifizierende Faktoren in der Pathogenese der Alzheimer-Krankheit
Eppendorf, U., & Naber, D. (1999)
Apolipoprotein E modulates c-secretase cleavage of the amyloid precursor protein
Irizarry, M. C., Deng, A., Lleó, A., Berezovska, O., Arnim, C. A. F. V., Martin-Rehrmann, M. D., Manelli, A. M., Jo, M., Hyman, B. T., & Rebeck, G. W. (2004)
Genetic and Expressional Studies of Alzheimer's Disease
Iivonen, S. (2005)
Beta-Amyloid-orientierte Therapien der Alzheimer-Krankheit
Grimmer, T. (2015) · DNP - Der Neurologe und Psychiater · doi:10.1007/s15202-015-0840-3
Pathological Consequences of Aβ From Extracellular to Intraneuronal
D’Andrea, M. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804256-4.00004-8
Apolipoprotein E Gene and Alpha 1-Antichymotrypsin Gene in Brain of Sporadic Alzheimer's Disease
Kim, S.-H., Han, S.-Y., Choi, Y.-S., & Lee, K. (2002) · Journal of the Korean Neurological Association
Alzheimer’s Disease Therapeutics Targeting Apolipoprotein E
Liao, F., & Holtzman, D. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00010-1
Analysis of β-Amyloid Peptide Degradation In Vitro.
Cordell, B., & Naidu, A. (2000) · Methods in Molecular Medicine · doi:10.1385/1-59259-195-7:139
Genetics and Neurobiology of Alzheimer’s Disease and Frontotemporal Dementias
George‐Hyslop, P. S. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-963-9_118
Cerebral white matter changes : Differentiating vascular and degenerative cognitive impairment
Stenset, V. T. V. (2009) · NORA - Norwegian Open Research Archives
Linking Alzheimer’s Disease, B-Amyloid, and Lipids
Ruppert, T., Hartmann, T., Pätzold, A. J., Zinser, E. G., Grimm, M. O. W., & Grimm, H. S. (2004) · CRC Press eBooks · doi:10.1201/9780203492185.ch9
Unravelling the genetic components of late onset Alzheimer's disease.
Hamilton, G. (2005) · OpenGrey (Institut de l'Information Scientifique et Technique)
Dorey, E. (2012) · uO Research (University of Ottawa) · doi:10.20381/ruor-6258
Phenotypic Impact of Genetic Risk Pathways for Alzheimer's Disease
Felsky, D. (2016) · TSpace (University of Toronto)
Carter, A. B. (2017) · D-Scholarship@Pitt (University of Pittsburgh)
Castranio, E. L. (2018) · D-Scholarship@Pitt (University of Pittsburgh)
Modelling the neurobiology of Alzheimer’s disease in vitro
Muñoz, S. S. (2019) · Research Online (University of Wollongong)
Bakir, I. (2010) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Saccades in Alzheimer’s disease: an MRI study.
Wright, S. L. (2011) · Otago University Research Archive (University of Otago)
Amyloid beta resistance and the Warburg effect: Re-examining Alzheimer's disease
Newington, J. T. (2013) · Scholarship@Western (Western University)
Ringelstein, E. B. (2001) · Steinkopff eBooks · doi:10.1007/978-3-642-57629-4_18
Dopico, A. M., Bukiya, A. N., & North, K. C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00014-6
Cellular Mechanisms of Dementia
Gan, L. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0054
&NA; (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199912000-00017
Microglia in the pathology of Alzheimer's disease
Wang, Y. (2023) · Theoretical and Natural Science · doi:10.54254/2753-8818/22/20230968
Feng, W., Zhang, Y., Wang, Z., Xu, H., Wu, T., Marshall, C., Gao, J., & Xiao, M. (2020) · Figshare · doi:10.6084/m9.figshare.13047485
Xu, G. M., Sacilotto, P., Gorski, C., Bali, P., Fromholt, S., Vo, Q., McFarland, K. N., Lu, Q., Borchelt, D., & Chakrabarty, P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.30.591932
Regulation of glial ApoE secretion by the mevalonate pathway is independent of ApoE isoform
Milstein, J. L., Kulas, J. A., Kamal, A., Lo, A. B., & Ferris, H. A. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251317732
Premenstrual dysphoric disorder as a potential predisposing factor for Alzheimer’s disease: a review
Yang, J., Cheng, M. T., Jiang, Z., Du, C., Zhao, J., Luo, Z.-L., & Zhang, Z. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1580947
Pillai, J. A., Bena, J., Bonner‐Jackson, A., & Leverenz, J. B. (2021) · Figshare · doi:10.6084/m9.figshare.13634443
Pillai, J. A., Bena, J., Bonner‐Jackson, A., & Leverenz, J. B. (2021) · Figshare · doi:10.6084/m9.figshare.13634449
Feng, W., Zhang, Y., Wang, Z., Xu, H., Wu, T., Marshall, C., Gao, J., & Xiao, M. (2020) · Figshare · doi:10.6084/m9.figshare.13047482
Valencia‐Olvera, A. C., Balu, D., Bellur, S., McNally, T. P., Saleh, Y., Pham, D., Ghura, S., York, J. M., Johansson, J. O., LaDu, M. J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24844648
Hashimoto, T., Fujii, D., Naka, Y., Kashiwagi‐Hakozaki, M., Matsuo, Y., Matsuura, Y., Wakabayashi, T., & Iwatsubo, T. (2020) · Figshare · doi:10.6084/m9.figshare.13346572
Valencia‐Olvera, A. C., Balu, D., Bellur, S., McNally, T. P., Saleh, Y., Pham, D., Ghura, S., York, J. M., Johansson, J. O., LaDu, M. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24844709
Valencia‐Olvera, A. C., Balu, D., Bellur, S., McNally, T. P., Saleh, Y., Pham, D., Ghura, S., York, J. M., Johansson, J. O., LaDu, M. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26654539
Pillai, J. A., Bena, J., Bonner‐Jackson, A., & Leverenz, J. B. (2021) · Figshare · doi:10.6084/m9.figshare.13634446
Mirian, C., Thastrup, M., Mathiasen, R., Schmiegelow, K., Olsen, J. V., & Østergaard, O. (2024) · Figshare · doi:10.6084/m9.figshare.26680394
Pillai, J. A., Bena, J., Bonner‐Jackson, A., & Leverenz, J. B. (2021) · Figshare · doi:10.6084/m9.figshare.13634455
Metadata
- Authors
- Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., Piccardo, P., Ghetti, B., & Paul, S. M.
- Affiliations
- Eli Lilly (United States) (US)
- Indiana University School of Medicine (US)
- Philipps University of Marburg (DE)
- Venue
- Nature Genetics
- Published
- 1997-11
- Volume
- 17
- Issue
- 3
- Pages
- 263-264
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1981554609
- Cited by
- 830
- References
- 14
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 27 · 2023: 18 · 2022: 25 · 2021: 19 · 2020: 27 · 2019: 24 · 2018: 16 · 2017: 21 · 2016: 20 · 2015: 19 · 2014: 21 · 2013: 16 · 2012: 20
- FWCI
- 26.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, amyloid-beta, amyloid deposition, Alzheimer's disease, APOE genotype, apolipoprotein E deficiency
- MeSH terms
- Age Factors, Alzheimer Disease, Animals, Apolipoproteins E, Brain, Humans, Immunohistochemistry, Mice, Inbred C57BL, Mice, Inbred DBA, Mice, Transgenic, RNA, Messenger, Polymerase Chain Reaction, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
